Complement deficiency and autoimmunity

Current Opinion in Pediatrics

Volumn 10, Issue 6, 1998, Pages 600-606

  Sullivan, Kathleen E ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COMPLEMENT;

AUTOIMMUNE DISEASE; COMPLEMENT DEFICIENCY; COMPLEMENT SYSTEM; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; GENETIC RISK; HUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0031723888     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199810060-00011     Document Type: Review

References (48)

1. Mori L, de Libero G: Genetic control of susceptibility to collagen-induced arthritis in T cell receptor b chain transgenic mice. Arthritis Rheum 1998, 41:256-262.
2. Sheerin NS, Springall T, Carroll MC, Hartley B, Sacks SH: Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice. Clin Exp Immunol 1997, 110:403-409.
3. Nangaku M, Alpers CE, Pippin J, Shankland SJ, Kurokawa K, Adler S, Johnson RJ, Couser WG: Renal microvascular injury induced by antibody to glomerular endothelial cells is mediated by C5b-9. Kidney Int 1997, 52:1570-1578.
4. Mongini PK, Vilensky MA, Highet PF, and Inman JK: The affinity threshold for human B cell activation via the antigen receptor complex is reduced upon co-ligation of the antigen receptor with CD21 (CR2). J Immunol 1997, 159:3782-3791. At low concentrations of antigen, costimulation with C3d lowers the affinity threshold for triggering B cells. Membrane bound IgM and CR2 coengagement is probably important in preimmune individuals.
5. Fang Y, Xu C, Fu Y-X, Holers M, Molina H: Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J Immunol 1998, 160:5273-5279. Expression of CR1/2 on follicular dendritic cells is required for normal humoral responses. These receptors act to trap antigen, which then stimulates germinal center B cells. C3d-decorated antigen could rescue B cells from apoptosis.
6. Fischer MB, Goerg S, Shen L, Prodeus AP, Goodnaow CG, Kelsoe G, Carroll MC: Dependence of germinal center B cells on expression of CD21/CD35 for survival. Science 1998, 280:582-585. In addition to providing an important costimulatory signal for B cells, this study demonstrates that signaling through CR1/2 receptors can provide an independent survival signal.
7. Korb LC, Ahearn JM: C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J Immunol 1997, 158:4525-4528.
8. Pasinetti GM, Tocco G, Sakhi S, Musllleh WD, DeSimoni MG, Mascarucci P, Schreiber S, Baudry M, Finch CE: Hereditary Deficiencies in complement C5 are associated with intensified neurodegenerative responses that implicate new roles for the C-system in neuronal and astrocytic functions. Neurobiol Dis 1996, 3:197-204.
9. Berkel Al, Retry F, Sanal O, Tinaztepe K, Ersoy F, Bakkaloglu A, Loos M: Development of systemic lupus erythematosus in a patient with selective complete C1q deficiency. Eur J Pediatr 1997, 156:113-115.
10. Bowness P, Davies KA, Norsworthy PJ, Athanassiou P, Taylor-Wiedeman J, Borysiewicz LK, Meyer PAR, Walport MJ: Hereditary C1q deficiency and systemic lupus erythematosus. Q J Med 1994, 87:455-464.
11. Hauptmann G, Tappeiner G, Schifferli JA: Inherited deficiency of the fourth component of complement. Immunodeficiency Rev 1988, 1:3-22.
12. Agnello V: Complement deficiency states. Medicine 1987, 57:1-23.
13. Botto M, Walport MJ, Kolble K, Reid KB: Hereditary deficiency of C3 in animals and humans. Genetic deficiencies of the complement system and association with disease-early components. Int Rev Immunol 1993, 10:37-50.
14. Retry F, Berkel Al, Loos M: Multiple identification of a particular type of hereditary C1q deficiency in the Turkish population: review of the cases and additional and functional analysis. Hum Genet 1997, 100:51-56. The largest mutation analysis study of C1q-deficient patients that has been published. It defines a mutation in C1qA that is common among people of southeast Europe and Turkey.
15. Petry F, Hauptmann G, Goetz J, Grosshans E, Loos M: Molecular basis of a new type of C1q-deficiency associated with a non-functional low molecular weight (LMW) C1q: paralleles and differences to other known genetic C1q defects. Immunopharmacology 1997, 38:189-201.
16. Johnson CA, Densen P, Hurford RK, Colten HR, Wetsel RA: Type I human complement C2 deficiency. J Biol Chem 1992, 267:9347-9353.
17. Ross SC, Densen P: Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine 1984, 63:243-273.
18. Figueroa JE, Densen P: Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991, 4:359-395.
19. Sullivan KE, Petri MA, Schmeckpeper BJ, McLean RH, Winkelstein JA: Prevalence of a mutation causing C2 deficiency in systemic lupus erythematosus. J Rheumatol 1994, 21:1128-1133.
20. Truedsson L, Alper CA, Awdeh ZL, Johansen P, Sjoholm AG, Sturfelt G: Characterization of type I complement C2 deficiency MHC haplotypes: strong conservation of the complotype/HLA-B-region and absence of disease association due to linked class II genes. J Immunol 1993, 151:5856-5863.
21. Wang X, Circolo A, Lokki M-L, Shackleford PG, Wetsel RA, Colten HR: Molecular heterogeneity in deficiency of complement protein C2 type I. Immunology 1998, 93:184-191. This study identified a unique mutation in exon 2 of C2 leading to C2 deficiency. This mutation was also associated with decreased expression of factor B.
22. Wetsel RA, Kulics J, Lokki M-L, Kiepiela P, Akama H, Johnson CAC, Densen P, Colten HR: Type II human complement C2 deficiency. Allele-specific amino acid substitutions (Ser189-Phe; Gly444-Arg) cause impaired C2 secretion. J Biol Chem 1996, 271:5824-5831.
23. Truedsson L, Gullstrand B, Jonsson T, Klint C, Welch TR, McAdams AJ, Beischel LS: Serum concentrations of C4 isotypes and factor B in type I C2 deficiency suggest haplotype-dependent quantitative expression of MHC class III complement genes. Exp Clin Immunogenet 1995, 12:66-73.
24. Traustadottir KH, Rafner BO, Steinsson K, Valdimarsson H, Erlendsson K: Participation of factor B in residual immune complex red cell binding activity observed in serum from a C2-deficient systemic lupus erythematosus patients may delay the appearance of clinical symptoms. Arthritis Rheum 1998, 41:427-434. Identification of factor B as being able to interact with C4 provides a potential explanation as to why C2-deficient patients are less susceptible to SLE than C1-or C4-deficient individuals.
25. Petri M, McLean RH, Watson R, Winkelstein JA: Clinical expression of systemic lupus erythematosus in patients with C4A deficiency. Medicine 1993, in press.
26. Davies EJ, Hillarby MC, Cooper RG: HLA-DQ, DR, and complement C4 variants in systemic lupus erythematosus. Br J Rheumatol 1993, 32:870-875.
27. Cornillet P, Gredy P, Pennaforte JL, Meyer O, Kazatchkine MD, Cohen JHM: Increased frequency of the long (S) allotype of CR1 (the C3b/C4b receptor, CD35) in patients with systemic lupus erythematosus. Clin Exp Immunol 1992, 89:22-25.
28. Christiansen FT, Zhang WJ, Griffiths M, Mallal SA, Dawkins RL: Major histocompatibility complex (MHC) complement deficiency, ancestral haplo-types and systemic lupus erythematosus (SLE): C4 deficiency explains some but not all of the influence of the MHC. J Rheumatol 1991, 18:1350-1358.
29. Yamada H, Watanabe A, Mimori A, Nakano K, Takeuchi F, Matsuta K, Tanimoto K, Miyamoto T, Yukiyama Y, Tokunaga K, Yokohari R: Lack of gene deletion for complement C4A deficiency in Japanese patients with systemic lupus erythematosus. J Rheumatol 1990, 17:1054-1057.
30. Schroeder HW, Zhu ZB, March RE, Campbell RD, Berney SM, Nedospasov SA, Turetskaya RL, Atkinson TP, Go RC, Cooper MD, Volanakis JE: Susceptibility locus for IgA deficiency and common variable immunodeficiency in the HLA-DR3, -B8, -A1 haplotypes. Molec Med 1998, 4:72-86. IgA deficiency and common variable immunodeficiency are polygenic immunodeficiencies associated with many autoimmune diseases. Inheritance of the C4A*Q0-containing haplotype was significantly associated with IgA deficiency and common variable immunodeficiency in this large multiplex kindred.
31. Cucca F, Zhu Z-B, Khanna A, Cossu F, Congia M, Badiali M, Lampis R, Frau F, De Virgiliis S, Cao A, Arnone M, Piras P, Campbell RD, Cooper MD: Evaluation of IgA deficiency in Sardinians indicates a susceptibility gene is encoded within the HLA class III region. Clin Exp Immunol 1998, 111:76-80. In an effort to define the region of the C4A*Q0-containing haplotype that is associated with IgA deficiency, the authors exploited differences between Sardinians and northern Europeans. This study implicates the MHC class III region; however, C4A*Q0 is not specifically identified as a disease susceptibility gene.
32. Welch TR, Brickman C, Bishof N, Maringhini S, Rutkowski M, Frenzke M, Kantor N: The phenotype of SLE associated with complete deficiency of complement isotype C4A. J Clin Immunol 1998, 18:48-51. C4A-deficient patients with SLE have milder disease compared with C4-sufficient patients with SLE. Renal disease in particular was decreased in C4A-deficient patients.
33. Araujo MNT, Silva NP, Andrade LEC, Sato EI, Gerbase-DeLima M, Leser PG: C2 deficiency in blood donors and lupus patients: prevalence, clinical characteristics and HLA-associations in the Brazilian population. Lupus 1997, 6:462-466. This large study used C2 antigen detection to identify complete and heterozygous C2 deficiency in blood donors and patients with SLE from a racially mixed São Paulo population. The authors conclude that heterozygous C2 deficiency is a risk factor for SLE and that heterozygous C2-deficient patients SLE have some distinct clinical features.
34. Hartmann D, Fremeaux-Bacchi V, Weiss L, Meyer A, Blouin J, Hauptmann G, Kazatchkine M, Uring-Lambert B: Combined heterozygous deficiency of the classical complement pathway proteins C2 and C4. J Clin Immunol 1997, 17:176-184.
35. Davies EJ, Snowden N, Hillarby MC, Carthy D, Grennan DM, Thomson W, Ollier WER: Mannose-binding protein gene polymorphism in systemic lupus erythematosus. Arthritis Rheum 1995, 38:110-114.
36. Sullivan KE, Wooten C, Goldman D, Petri M: Mannose binding protein genetic polymorphisms in black patients with systemic lupus erythematosus. Arthritis Rheum 1996, in press.
37. Davies EJ, Teh L-S, Ordi-Ros J, Snowden N, Hillarby MC, Hajeer A, Donn R, Perez-Pemen P, Villardell-Tarres M, Ollier WER: A dysfunctional allele of the mannose binding protein gene associates with systemic lupus erythematosus in a Spanish population. J Rheumatol 1997, 24:485-488.
38. Graudal NA, Homann C, Madsen HO, Svejgaard A, Jurik AG, Graudal HK, Garred P: Mannan binding lectin in rheumatoid arthritis: a longitudinal study. J Rheumatol 1998, 25:629-635. The authors studied 112 Caucasian patients with rheumatoid arthritis prospectively; 11% were found to have no detectable MBP compared with 3% of a control population. Arthritis patients with low or absent MBP levels were more likely to have early onset disease, high joint swelling scores, and progressive destruction by radiologic criteria.
39. Kakkanaiah VN, Shen GQ, Ojo-Amaize EA, Peter JB: Association of low concentrations of serum mannose-binding protein with recurrent infections in adults. Clin Diagnost Lab Immunol 1998, 5:319-321. Adults and children with recurrent infection were evaluated for low MBP levels. Low MBP serum levels were found in 22% of the pediatric patients and 38% of the adult patients compared with 4% of the controls.
40. Garred P, Madsen HO, Balslev U, Hofmann B, Pedersen C, Gerstoft J, Svejgaard A: Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997, 349:236-240.
41. Suankratay C, Zhang X-H, Zhang Y, Lint TF, Gewurz H: Requirement for the alternative pathway as well as C4 and C2 in complement-dependent hemolysis via the lectin pathway. J Immunol 1998, 160:3006-3013.
42. Homann C, Varming K, Hogasen K, Molines TE, Graudal N, Thomsen AC, Garred P: Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality. Gut 1997, 40:544-549.
43. Hasely LA, Wisnieski JJ, Denburg MR, Michael-Frossman AR, Ginzler EM, Gourley MF, Hoffman JH, Kimberly RP, Salmon JE: Antibodies to C1q in systemic lupus erythematosus: characteristics and relation to Fc gamma RIIA alleles. Kidney Int 1997, 52:1375-1380. This important study evaluates antibodies to C1q as disease markers in SLE. Antibodies to C1q were highly associated with renal disease and titers correlated with treatment response. Inheritance of a low binding allele of FcγRIIAFN1AU: pls verify term; can it be spelled out? appeared to be a risk factor for developing antibodies to C1q.
44. Ravelli A, Wisnieski JJ, Ramenghi B, Ballardini G, Zonta L, and Martini A: IgG autoantibodies to complement C1q in pediatric-onset systemic lupus erythematosus. Clin Exp Rheumatol 1997, 15:215-219.
45. He S, and Lin Y-L: In vitro stimulation of C1s proteolytic activities by C1s-presenting autoantibodies from patients with systemic lupus erythematosus. J Immunol 1998, 160:4641-4647. A new autoantibody in SLE is described, in which antibodies to C1s enhance cleavage of C4. The antibodies both stimulate C s activity and enhance conversion of latent C1s to active C1s. Overactivation of complement is hypothesized to induce tissue damage and lead to presentation of self antigens to B cells.
46. Skattum L, Martensson U, Sjoholm AG: Hypocomplementemia caused by C3 nephritic factors (C3 NeF): clinical findings and the coincidence of C3 NeF type II with anti-C1q antibodies. J Int Med 1997, 242:455-464. This study emphasizes the heterogeneous clinical manifestations of C3 nephritic factors. Six of the patients with C3 nephritic factors also had antibodies to C1q. Membranoproliferative glomerulonephritis, partial lipodystrophy, Schönlein-Henoch purpura, SLE, and infection were seen in this population.
47. Botto M, Dell'Agnola C, Pandolfi PP, Bygrave A, Thompson M, Petry F, Loos M, Walport MJ: Homozygous C1q deficiency: a cause of systemic lupus erythematosus in humans and mice. Arthritis Rheum 1997, 40(suppl):S122.
48. Takahashi K, Kozono Y, Waldschmidt TJ, Berthiaume D, Quigg RJ, Baron A, Holers VM: Mouse complement receptors type I (CR1;CD35) and type 2 (CR2;CD21)? expression on normal B cell populations and decreased levels during the development of autoimmunity in MRL/1 pr mice. J Immunol 1997, 159:1557-1569. Expression of CR1 and CR2 is decreased in human patients with SLE This study identified a similar phenomenon in a well-studied murine SLE model. The decrease in CR1/2 receptors preceeded clinical disease, suggesting that it may be part of the pathologic process.